The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Leadership - GOG Foundation; GOG Foundation
Consulting or Advisory Role - Abbvie; Aravive; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; Janssen; Merck; Mersana; Novocure; OncoQuest; OncXerna Therapeutics; Onxeo; Roche/Genentech; Zentalis
Research Funding - Genentech; Genmab; Immunogen; Merck
Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in BRCA wild-type patients with recurrent ovarian cancer.
 
Robert L. Coleman
No Relationships to Disclose
 
Jessica Perhanidis
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - Boston Scientific; GlaxoSmithKline
 
Linda Kalilani
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Nicole M. Zimmerman
Employment - GlaxoSmithKline
 
Amanda Golembesky
Employment - GlaxoSmithKline
 
Kathleen N. Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - AADi; Alkermes (Inst); AstraZeneca; Blueprint Medicines (Inst); Caris Life Sciences; Clovis Oncology; Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); Hengrui Pharmaceutical; I-Mab (Inst); Immunogen; InxMed (Inst); Iovance Biotherapeutics; Merck; Mereo BioPharma; Mersana (Inst); Myriad Genetics; Novartis; Novartis/Pfizer; Onconova Therapeutics; OncXerna Therapeutics; VBL Therapeutics; Verastem/Pharmacyclics
Research Funding - Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline
Other Relationship - GOG Partners (Inst)